4.8 Article

Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks

Journal

NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/ncomms11938

Keywords

-

Funding

  1. BLUEPRINT project (European Union's Seventh Framework Programme) [282510]
  2. ERA-NET project EpiMark (FWF grant) [I 1575-B19]
  3. ERA-NET project CINOCA (FWF grant) [I 1626-B22]
  4. Feodor Lynen Fellowship of the Alexander von Humboldt Foundation
  5. Bloodwise [11052, 12036]
  6. Kay Kendall Leukaemia Fund [873]
  7. Cancer Research UK [C34999/A18087, ECMC C24563/A15581]
  8. Wessex Medical Research
  9. Bournemouth Leukaemia Fund
  10. New Frontiers Group award of the Austrian Academy of Sciences
  11. Austrian Science Fund (FWF) [I 1626] Funding Source: researchfish
  12. Austrian Science Fund (FWF) [I1626] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

Chronic lymphocytic leukaemia (CLL) is characterized by substantial clinical heterogeneity, despite relatively few genetic alterations. To provide a basis for studying epigenome deregulation in CLL, here we present genome-wide chromatin accessibility maps for 88 CLL samples from 55 patients measured by the ATAC-seq assay. We also performed ChIPmentation and RNA-seq profiling for ten representative samples. Based on the resulting data set, we devised and applied a bioinformatic method that links chromatin profiles to clinical annotations. Our analysis identified sample-specific variation on top of a shared core of CLL regulatory regions. IGHV mutation status-which distinguishes the two major subtypes of CLL-was accurately predicted by the chromatin profiles and gene regulatory networks inferred for IGHV-mutated versus IGHV-unmutated samples identified characteristic differences between these two disease subtypes. In summary, we discovered widespread heterogeneity in the chromatin landscape of CLL, established a community resource for studying epigenome deregulation in leukaemia and demonstrated the feasibility of large-scale chromatin accessibility mapping in cancer cohorts and clinical research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available